Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 793-795, 2004; 10.1373/clinchem.2004.032177
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diamandis, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diamandis, E. P.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2004;50:793-795.)
© 2004 American Association for Clinical Chemistry, Inc.

Editorials

How Are We Going to Discover New Cancer Biomarkers? A Proteomic Approach for Bladder Cancer

Eleftherios P. Diamandis1

1 Department of Pathology, and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario M5G 1X5, Canada and Department of Laboratory Medicine, and Pathobiology, University of Toronto, Toronto, Ontario, Canada, E-mail ediamandis@mtsinai.on.ca

The first 300 words of the full text of this article appear below.

A handful of cancer biomarkers are currently used routinely for population screening, disease diagnosis, prognosis, monitoring of therapy, and prediction of therapeutic response. Unfortunately, most of these biomarkers suffer from low sensitivity, specificity, and predictive value, particularly when applied to rare diseases in population screening programs. Thus, for the classic cancer biomarkers much is left to be desired in terms of clinical applicability. We need new cancer biomarkers that will further enhance our ability to diagnose, prognose, and predict therapeutic response in many cancer types. Because biomarkers can be analyzed relatively noninvasively and economically, it is worth investing in discovering more biomarkers in the future. The completion of the Human Genome Project has raised expectations that the knowledge of all genes and proteins will lead to identification of many candidate biomarkers for cancer and other diseases. These predictions still need to be realized. The prevailing view among specialists is that the most powerful single cancer biomarkers may have already been discovered. Likely, in the future we will discover biomarkers that are less sensitive or specific but could be used in panels, in combination with powerful bioinformatic tools, to devise diagnostic algorithms with improved sensitivity and specificity. These efforts are currently in progress (1).

Most of the currently used cancer biomarkers were discovered after development of novel analytical techniques such as immunologic assays and the monoclonal antibody technology. Animals were immunized with extracts from tumors or cancer cell lines, followed by screening of hybridomas for monoclonal antibodies that recognize "cancer-associated" antigens. More recently, and with the completion of the Human Genome Project, many researchers have hypothesized that the best cancer biomarkers will likely be secreted proteins (2). Approximately 20–25% of all cell proteins are secreted. However, this is not an absolute requirement because many classic cancer biomarkers, . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
H. Kawanishi, Y. Matsui, M. Ito, J. Watanabe, T. Takahashi, K. Nishizawa, H. Nishiyama, T. Kamoto, Y. Mikami, Y. Tanaka, et al.
Secreted CXCL1 Is a Potential Mediator and Marker of the Tumor Invasion of Bladder Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2579 - 2587.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Seam, D. A. Gonzales, S. J. Kern, G. L. Hortin, G. T. Hoehn, and A. F. Suffredini
Quality Control of Serum Albumin Depletion for Proteomic Analysis
Clin. Chem., November 1, 2007; 53(11): 1915 - 1920.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
L. J. Dekker, W. Boogerd, G. Stockhammer, J. C. Dalebout, I. Siccama, P. Zheng, J. M. Bonfrer, J. J. Verschuuren, G. Jenster, M. M. Verbeek, et al.
MALDI-TOF Mass Spectrometry Analysis of Cerebrospinal Fluid Tryptic Peptide Profiles to Diagnose Leptomeningeal Metastases in Patients with Breast Cancer
Mol. Cell. Proteomics, September 1, 2005; 4(9): 1341 - 1349.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.